Organic anion transporting polypeptide (OATP) 1B1 mediates the hepatic uptake of many drugs including lipid-lowering statins. Decreased OATP1B1 transport activity is often associated with increased systemic exposure of statins and statin-induced myopathy. Antimalarial drug chloroquine (CQ) is also used for long-term treatment of rheumatoid arthritis and systemic lupus erythematosus. CQ is lysosomotropic and inhibits protein degradation in lysosomes. The current studies were designed to determine the effects of CQ on OATP1B1 protein degradation, OATP1B1-mediated transport in OATP1B1-overexpressing cell line, and statin uptake in human sandwich-cultured hepatocytes (SCH). Treatment with lysosome inhibitor CQ increased OATP1B1 total protein levels in HEK293-OATP1B1 cells and in human SCH as determined by OATP1B1 immunoblot. In HEK293-FLAG-tagged OATP1B1 stable cell line, co-immunofluorescence staining indicated that intracellular FLAG-OATP1B1 is colocalized with lysosomal associated membrane glycoprotein (LAMP)-2, a marker protein of late endosome/lysosome. Enlarged LAMP-2-positive vacuoles with FLAG-OATP1B1 protein retained inside were readily detected in CQ-treated cells, consistent with blocking lysosomal degradation of OATP1B1 by CQ. In HEK293-OATP1B1 cells, without pre-incubation, CQ concentrations up to 100 μM did not affect OATP1B1-mediated [ 3 H]E 2 17G accumulation. However, pre-incubation with CQ at clinically , which also have lysosome inhibition activity, significantly decreased OATP1B1-mediated transport in HEK293-OATP1B1 cells. Pharmacoepidemiologic studies using data from the U.S. Food and Drug Administration Adverse Event Reporting System indicated that CQ plus pitavastatin, rosuvastatin, and pravastatin, which are minimally metabolized by the cytochrome P450 enzymes, led to higher myopathy risk than these statins alone. In summary, the present studies report novel findings that lysosome is involved in degradation of OATP1B1 protein and that pre-incubation with lysosomotropic drug CQ downregulates OATP1B1 transport activity. Our in vitro data in combination with pharmacoepidemiologic studies support that CQ has potential to cause OATP-mediated drug-drug interactions.
Introduction
Drug-drug interactions (DDIs), which often lead to adverse drug effects, are a major concern in patients receiving multidrug therapy. 1 The organic anion-transporting polypeptides (OATPs) belong to the solute carrier organic anion (SLCO) transporter superfamily. 2 OATP1B1 is predominantly expressed on the basolateral membranes of hepatocytes and mediates the hepatic uptake of many drugs such as HMG-CoA reductase inhibitor statins, rifampicin, and paclitaxel as well as endogenous compounds. 3, 4 Decreased transport activity of OATP1B1 due to genetic variation [e.g., the single nucleotide polymorphism (SNP) V174A of OATP1B1] and DDIs is often associated with increased systemic exposure of statins and statin-induced myopathy. [5] [6] [7] OATP1B1 has been recognized as an important determinant of transporter-mediated DDIs. 8 Chloroquine (CQ), a 4-aminoquinoline class of drug, is a lysosomotropic agent that accumulates preferentially within the lysosome. It increases the intralysosomal pH, 9 and inhibits lysosomal degradation of proteins including many transport proteins such as glutamate transporter 10 and glucose transporter (GLUT) 1 and 2. 11, 12 The effect of CQ on OATP1B1 protein degradation has not been reported. CQ interacts with several transporters as substrate and/or inhibitor. CQ is a substrate and inhibitor of multidrug and toxin extrusion (MATE) 1. 13 It also inhibits substrates transport mediated by P-glycoprotein (P-gp) 14 breast cancer resistance protein (BCRP) 14 and OATP1A2. 15 In rat sandwich-cultured hepatocytes (SCH), pretreatment with 10 μM CQ for 48 h significantly decreased total accumulation of rosuvastatin in cells and bile canaliculi. 16 Since rosuvastatin is a substrate of multiple transporters including OATP1B1, 17 we hypothesize that CQ pretreatment may modulate the transport function of OATP1B1.
In addition to being used for treatment of malaria and amebic infection, 18 CQ is also used for long-term treatment of rheumatoid arthritis and systemic lupus erythematosus. [19] [20] [21] [22] It is currently in clinical trials for cancer therapy either alone [23] [24] [25] or in combination with chemotherapy drugs. 26, 27 Considering the widespread use of statins in cardiovascular diseases, concurrent administration of statins and CQ is likely. To the best of our knowledge, the effects of CQ on systemic exposure of statins and statin-associated myopathy have not been reported in clinical studies. The FDA Adverse Event Reporting System (FAERS) is a database that contains information on adverse events and medication error reports submitted to the FDA. 28 This database is designed to support the FDA's postmarketing safety surveillance program for drug and therapeutic biologic products. The FAERS has been widely used for pharmacoepidemiologic studies including assessing statin-related myopathy risk due to DDIs. 29, 30 The current studies were designed to determine the effects of CQ on OATP1B1 protein degradation, OATP1B1-mediated transport in OATP1B1-overexpressing cell line, and statin uptake in human SCH. The myopathy risk was also compared in patients concomitantly taking CQ and statins vs statins alone using data from the FAERS.
The effects of CQ on OATP1B1 protein degradation and transport activity were determined in HEK293 stable cell lines overexpressing OATP1B1 (HEK293-OATP1B1) or FLAGtagged OATP1B1 (HEK293-FLAG-OATP1B1). Pitavastatin and estradiol 17β-D-glucuronide (E 2 17G), which are sensitive OATP1B1 substrates for studying the inhibition of OATP1B1 transport activity in vitro, 31 were used as OATP1B1 probe substrates in HEK293-OATP1B1
and -FLAG-OATP1B1 stable cell lines. The effect of CQ on hepatic uptake of therapeutic drug pitavastatin was also determined in the physiologically relevant human SCH model. Pitavastatin, pravastatin, and rosuvastatin are OATP1B1 substrates 32 and are minimally metabolized by the cytochrome P450 enzymes. [33] [34] [35] These three statins were selected in current pharmacoepidemiologic studies to determine whether CQ plus statins (pitavastatin, rosuvastatin, and pravastatin) leads to a higher risk for myopathy than these statins alone, using data from the FAERS.
1% antibiotic and antimycotic solution, and 600 μg/mL Geneticin (Life Technologies, Grand Island, NY). Cells were cultured in a humidified atmosphere (95% O 2 , 5% CO 2 ) at 37 °C.
Human Sandwich-Cultured Hepatocytes (SCH)
Human hepatocytes were purchased from Triangle Research Laboratories, LLC (Research Triangle Park, NC). Demographics of the donors are listed in Table 1 . Human SCH were cultured as described previously. 40 In brief, on day 0, cells were plated at 3.5 × 10 5 cells per well in 24-well Biocoat culture plates in phenol red free DMEM containing 5% (v/v) FBS, 1% (v/v) MEM NEAA, 2 mM L-glutamine, 100 units of penicillin G sodium/mL, 100 g/mL of streptomycin sulfate, 1 μM dexamethasone, and 4 μg/mL insulin. Cells were cultured at 37 °C in a humidified incubator (95% O 2 , 5% CO 2 ). At 6 h after seeding, when the cells were attached to the plate, cells were overlaid with Matrigel at a final concentration of 0.25 mg/mL in phenol red free DMEM supplemented with 2 mM L-glutamine, 1% (v/v) MEM NEAA, 100 units/mL of penicillin G sodium, 100 g/mL of streptomycin sulfate, 0.1 μM dexamethasone, and 1% (v/v) ITS + premix. Culture medium was replaced every 24 h. Uptake experiments were conducted on day 2 of culture.
Immunoblotting
Immunoblotting was conducted similarly to those described previously. 41 In brief, cells were seeded at a density of 1.1 × 10 5 cells per well in 24-well culture plates precoated with poly-L-lysine and cultured for 48 h. Two cell lysis methods (with or without trypsinization) were compared to optimize the OATP1B1 immunoblot. After aspirating culture media and rinsing once with DPBS, whole cell lysates (WCL) were prepared by adding ice cold lysis buffer, which contained 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.5% Na-deoxycholate, and Complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), either directly onto the cells in culture plate (without trypsinization) or to cell pellets collected after trypsinization with 1× Trypsin/EDTA (Sigma-Aldrich, St. Louis, MO) and subsequent washing with DPBS (with trypsinization). Whole cell lysates (WCL) (50 μg) were resolved on 10% SDS-PAGE (Bio-Rad, Hercules, CA). Proteins were then transferred to nitrocellulose membranes and subsequently probed with the following primary antibodies: rabbit polyclonal OATP1B1 antibody (Fisher Scientific Company, LLC, Denver, CO) custom-generated according to a previous publication (1:1000 dilution), 43 rabbit polyclonal anti-FLAG antibody (1:4000 dilution) and mouse monoclonal anti-β-actin antibody (1:5000 dilution) (Sigma-Aldrich, St. Louis, MO), mouse monoclonal anti-GAPDH antibody (1:2000) (Santa Cruz Biotechnology, Inc., Dallas, TX), and anti-alpha 1 sodium potassium ATPase antibody (1:8000 dilution) (Abcam, Cambridge, MA). After incubation with HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Dallas, TX), signals were detected by Supersignal West Duro (Pierce, Rockford, IL) using a Bio-Rad ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA). Image Lab v4.1 software (Bio-Rad Laboratories, Hercules, CA) was used to perform the densitometry analysis.
Immunofluorescence Staining
Experiments were conducted similarly to those published previously, with slight modifications. 44 In brief, HEK293-FLAG-OATP1B1 cells were grown to confluence on poly-L-lysine coated coverslips in 24-well plates. Cells were fixed for 20 min with methanol, permeabilized with Triton X-100 (0.25%) in DPBS for 10 min at room temperature, and blocked with 5% BSA in DPBS for 1 h at room temperature. For co-immunofluorescence staining of FLAG-OATP1B1 and LAMP-2, cells were co-incubated with the rabbit polyclonal anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO, 1:100 dilution) and mouse monoclonal antibody of LAMP-2 (Clone H4B4, Santa Cruz Biotechnology, Inc., Dallas, TX, 1:50 dilution) at 37 °C for 2 h. After washing 3 times with DPBS, cells were co-incubated with secondary antibodies Alexa Fluor 488-conjugated goat anti-mouse IgG (Life Technologies, Grand Island, NY, 1:200 dilution) and Alexa Fluor 594-conjugated goat antirabbit IgG (Life technologies, Grand Island, NY, 1:200 dilution) at 37 °C for 1 h. Both primary and secondary antibodies were diluted in DPBS containing 5% BSA. Diamidino-2-phenylindole (DAPI) (300 nM) was used for counterstaining nuclei. After washing, the coverslips were mounted on glass slides with ProLong gold antifade reagent (Life Technologies, Grand Island, NY). Images were taken using Leica SP2 MP (Leica Microsystems, Inc., Buffalo Grove, IL) or Olympus FV1000 (Olympus Scientific Solutions Americas Corp., Waltham, MA) confocal microscopes as indicated in the figure legends.
Transport Studies
Transport studies in HEK293 stable cell lines and in human SCH were conducted similarly to those described previously. 41, 42 HEK293-OATP1B1, -FLAG-OATP1B1, and -Mock cells were seeded at a density of 0.8-1.1 × 10 5 cells/well in 24-well culture plates precoated with poly-L-lysine and were cultured for 48-72 h. Cells from stable cell lines or human SCH were either pretreated with culture medium containing CQ, monensin, bafilomycin A1, or vehicle control for the designated times or not pretreated. 0.1% DMSO was used as vehicle control for monensin and bafilomycin A1 treatment. As CQ stock (50 mM) was resolved in water, CQ-free fresh medium was used as vehicle control for CQ pretreatment. To determine the effects of CQ on OATP1B1-mediated transport after prolonged treatment, HEK293-OATP1B1 cells were preincubated with CQ-free (CTL) or 25 μM CQ-containing medium for 2 h. At the end of pre-incubation, the culture medium was aspirated and CTL cells were cultured in CQ-free medium and cells pretreated with 25 μM CQ were cultured in medium containing 1.5 μM CQ, for the indicated time, up to 24 h.
At the time of uptake experiments, after rinsing with prewarmed (37 °C) HBSS buffer (pH 7.4) three times, cells were incubated with HBSS containing [ 3 H]E 2 17G (1 μM, 2 min) or [ 3 H]pitavastatin (1 μM, 0.5 min) in the absence or presence of testing drugs (CQ or rifampicin). At the end of incubation, the buffer was aspirated rapidly, and the cells were rinsed with ice-cold HBSS three times and then lysed with Triton X-100 (0.5% v/v) in DPBS. An aliquot of the lysate was subjected to liquid scintillation counting (LS6500 scintillation counter, Beckman Coulter, Brea, CA). Substrate accumulation was normalized to protein concentration determined by BCA assay (Pierce Chemical, Rockford, IL) and corrected for nonspecific binding of the substrate by including a non-overlaid poly-L-lysine coated blank plate for uptake studies in stable cell lines and a Matrigel overlaid blank plate for human SCH, respectively. 
Lactate Dehydrogenase (LDH) Cytotoxicity Assay
Experiments were conducted similarly to those published previously. 45 After treatment with CQ, monensin, bafilomycin A1, or respective vehicle control, cell culture medium was assayed for LDH activity with a cytotoxicity detection kit (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions. Triton X (2%) treated and non-treated cells served as the 100% cytotoxicity positive control and negative control, respectively.
Pharmacoepidemiologic Studies Using the FDA Adverse Event Reporting System (FAERS)
Studies using the FAERS database were similar to those published previously. 29 All of the adverse event case reports from quarter 1 of 2004 to quarter 3 of 2012 were used for data analysis (n = 6.47 millions). The myopathy adverse event was defined as published previously. 29 It includes all the mild or severe myopathy symptoms. The drug names and their synonyms were mapped based on their DrugBank 46 drug names. Our drug interaction hypothesis was whether CQ plus statins (pitavastatin, rosuvastatin, and pravastatin) leads to higher myopathy risk than these statins alone. A similar hypothesis was posed to test the interactions between sulfonylureas and statins in our previous work. 47 The interaction between CQ and statins was further tested in different subpopulations defined by age and gender.
Data Analysis
For the statistical analysis in Figures 4, 5, 6 and 7B, fold changes and associated standard errors (SEs) were estimated by generalized linear mixed models with the log link function, a fixed effect (treatment time or group), and a random effect (experiment date or hepatocyte donor), adjusting for treatment time/group-specific overdispersion. In the case of multiple comparisons, p-values were adjusted based on Bonferroni's method. The Chi-square test and Student's t test were used for statistical analysis in Table 3 and the Figure 8 inset, respectively. A two-sided p-value of <0.05 defines statistical significance. SAS software (version 9.3, Cary, NC) was used for statistical analyses.
Results

Estimation of the Maximum Unbound CQ Concentration at the Inlet to the Liver
The I u,in,max of CQ was estimated to be 18.3-23.4, 28.2, and 56.8 μM based on data in rheumatoid arthritis patients chronically treated with CQ at a daily dose of 191 mg 48 and after a 300 and 600 mg single dose of CQ in healthy volunteers, 39, 49 respectively (Table 2) . CQ concentrations of 2.5-25 μM, which are clinically relevant, were used in subsequent experiments.
CQ Treatment Increased Total Protein Levels of OATP1B1 in HEK293-OATP1B1 Cells and in Human SCH
Initially, we tested the specificity of our custom-generated OATP1B1 antibody and optimized OATP1B1 immunoblot protocol by comparing two cell lysis methods, directly lysing the cells in the culture plate without trypsinization and lysing the cell pellets collected after trypsinization. As shown in Figure 1 , OATP1B1 antibody specifically detected OATP1B1 in HEK293-OATP1B1 stable cell line but not in negative control HEK293-Mock (Mock) cells in whole cell lysates prepared with both methods. In cells that were lysed directly in the culture plates without trypsinization, the molecular weight of OATP1B1 detected by the OATP1B1 antibody was ∼90 kDa. A lower molecular weight band of OATP1B1 (∼64 kDa) was prominent in cell lysates prepared from trypsinized HEK293-OATP1B1 cells, while this band was negligible in cells lysed directly without trypsinization. Since the molecular weight of OATP1B1 (∼90 kDa) that resulted from the direct lysis method is similar to that published previously, 3 this method was used to prepare whole cell lysates for immunoblot in subsequent experiments.
To determine the involvement of lysosome in degradation of OATP1B1, total protein levels of OATP1B1 were compared in HEK293-OATP1B1 cells treated with CQ or CTL by OATP1B1 immunoblotting. Treatment with 25 μM CQ for 2 and 5 h and 100 μM CQ for 5 h increased OATP1B1 total protein levels to 1.2 ± 0.1, 1.5 ± 0.1 and 1.5 ± 0.3 fold of control, respectively ( Figure 2A ).
Increased total protein levels of Na,K-ATPase following lysosome inhibition by CQ treatment were reported previously. 50 In the current studies, we used Na,K-ATPase as a positive control for increased total protein levels following lysosome inhibition. As shown in Figure 2B , treatment with CQ (25 μM) for 2 and 5 h increased Na,K-ATPase total protein levels to 1.2 ± 0.1 and 1.4 ± 0.2 fold of control, respectively.
Total protein levels of endogenous OATP1B1 were also compared in human SCH treated with CQ or vehicle control. As shown in Figure 2C , treatment with 10 μM CQ for 5 h increased OATP1B1 protein levels to 1.7 ± 0.5 fold of control in human SCH (ranging from 1.2-2.1-fold of control, n = 3 donors). In human SCH, a major OATP1B1 band at ∼64 kDa was observed ( Figure 2C ), similar as published previously. 51 Alam et al. 
Pretreatment Effects and Direct Inhibition of CQ on OATP1B1-Mediated Transport
To determine the pretreatment effects of CQ on OATP1B1-mediated transport, HEK293-OATP1B1 or -FLAG-OATP1B1 was preincubated with CQ or vehicle CTL at indicated concentrations for 0. The effect of CQ on OATP1B1-mediated [ 3 H]E 2 17G accumulation was further compared between two scenarios, a pre+co-incubation scenario, when [ 3 H]E 2 17G accumulation (1 μM, 2 min) was determined in the presence of 100 μM CQ after pre-incubation with CQ (100 μM, 5 h), and a co-incubation scenario as described above. For comparison purposes, 100 μM CQ co-incubation data in Figure 4D was replotted in Figure 4E . Under pre+co-incubation conditions, [ 3 H]E 2 17G accumulation decreased to 0.432 ± 0.02 fold compared to values measured under the co-incubation condition (p < 0.001, Figure 4E ). The LDH assay showed negligible toxicity after 5 h treatment with 100 μM CQ in HEK293-OATP1B1 cells ( Figure S3A ).
Effects of Monensin and Bafilomycin A1 on OATP1B1-Mediated Transport
Three classes of compounds are frequently used to elevate the pH in endosome and other acidic organelles, which include lysosomotropic weak bases (e.g., chloroquine 54 ), carboxylic ionophores (e.g., monensin 55 ), and inhibitors of vacuolar H + -ATPase (e.g., bafilomycin A1 56 ) (reviewed by Huotari 57 ). In addition to CQ, monensin and bafilomycin A1 are also reported to inhibit endosome-lysosome system acidification and lysosome activity. 58, 59 We determined whether pretreatment with monensin or bafilomycin A1 also affects OATP1B1-mediated Figure 5B ). The LDH assay showed negligible toxicity after monensin and bafilomycin A1 treatment in HEK293-OATP1B1 cells ( Figure S3A ).
Effects of CQ on OATP1B1-Mediated Transport after Prolonged Treatment
CQ is administered daily for long-term treatment of rheumatoid arthritis and lupus. 22 In patients who had been taking CQ for at least six months, the dose normalized average unbound steady state concentration (C ss ) of CQ is ∼1.7 μM. 48 The effect of CQ on OATP1B1-mediated transport after prolonged treatment was determined in HEK293-OATP1B1 cells. After 2 h treatment with CQ-free medium or medium containing 25 μM CQ, cells were subsequently cultured in CQ-free medium or 1.5 μM CQ-containing medium, 
Pretreatment with CQ Significantly Decreased [ 3 H]-Pitavastatin Accumulation in Human SCH
The effects of CQ on OATP1B1 transport function was further determined in the physiologically relevant human SCH model with [ 3 H]pitavastatin 60 as a probe substrate.
[ 3 H]Pitavastatin (1 μM) accumulation in human SCH was linear at least up to 5 min ( Figure   7A ). An incubation time of 0.5 min was used for subsequent uptake experiments in human SCH. Pretreatment with CQ (10 μM, 5 h) significantly decreased [ 3 H]pitavastatin accumulation to 0.65 ± 0.084 fold of control (p < 0.01 vs control, Figure 7B ). The LDH assay showed negligible toxicity after 5 h treatment with CQ at 10 μM ( Figure S3C ).
DDIs Associated with Increased Risk of Myopathy
To determine whether CQ plus statins (rosuvastatin, pravastatin, and pitavastatin) leads to higher myopathy risk than these statins alone, pharmacoepidemiological studies were conducted using data from the FAERS database. As shown in Table 3 , among all patient data, CQ plus statins led to 17.2% myopathy risk compared to statins alone, 9.2%. The relative risk (RR) is 1.87 with a p-value of 0.05. It has been reported that the female gender and advanced age are associated with higher risk for myopathy. 61 Therefore, the interaction effect between CQ and statins was further analyzed within the subpopulations. The only subpopulation that showed significant CQ and statin DDIs was women. In women, CQ plus statins significantly increased the myopathy risk from 9.6% to 21.9% (Relative Risk = 2.28, p < 0.05 vs. statins alone). In other subpopulation analyses, men, >50 years, and <50 years, the CQ plus statins all showed increased myopathy risk, but were not statistically significant.
Effects of CQ on Transport Kinetics of [ 3 H]E 2 17G in HEK293-OATP1B1 Cells
As shown in Figure 8 
Discussion
Understanding the mechanism(s) underlying altered transport activity of OATP1B1 has significant relevance in predicting potential OATP1B1-mediated DDIs. The current study demonstrates that the lysosome pathway is involved in degradation of OATP1B1, and that pre-incubation with lysosomotropic drug CQ downregulates OATP1B1-mediated transport. Pharmacoepidemiologic studies using data from the FAERS indicated that CQ plus statins (pitavastatin, rosuvastatin, and pravastatin) led to a greater myopathy risk than these statins alone.
Plasma membrane proteins are constitutively subjected to endocytosis. 57 A portion of the internalized cargo is transported via late endosome for degradation by lysosomes. 57 Treatment with CQ increased the total protein levels of OATP1B1 expressed exogenously in HEK293-OATP1B1 cells and endogenously in human SCH (Figure 2A,C) . Increased total protein levels of membrane proteins following CQ treatment was reported previously for bone morphogenic protein type II receptor (BMPR-II), 62 the transmembrane protein β-site amyloid precursor protein cleaving enzyme (BACE), 63 and Na,K-ATPase. 50 Increased Na,K-ATPase total protein levels following CQ treatment was also detected in current studies ( Figure 2B ), consistent with previous report. 50 Plasma membrane localization of OATP1B1 has been detected by immunofluorescence staining in several reports. 3, 53, 64 However, association of intracellular OATP1B1 with subcellular organelles has not been reported. Current studies demonstrated that, in addition to plasma membrane localization, the intracellular FLAG-OATP1B1 proteins were localized to LAMP-2 positive late endosomes/lysosomes in HEK293-FLAG-OATP1B1 cells without CQ treatment and under lysosome inhibition following CQ treatment ( Figure 3 and Figure S2 merged images). Overall, increased total protein levels of OATP1B1 upon CQ treatment and localization of OATP1B1 with LAMP-2 suggest that the lysosome pathway is involved in the degradation of OATP1B1 proteins. 65 In the current studies, we focused on determining whether clinically relevant concentrations of CQ affect OATP1B1 transport activity and statin uptake in human SCH. The estimated I u,in,max of CQ is 18.3-56.8 μM ( Table 2 ). The unbound C ss of CQ in the plasma is ∼1.7 μM in rheumatoid arthritis patients treated with CQ daily for long-term. 48 In HEK293 accumulation were significantly less than those in the CQ-free treatment CTL ( Figure 6 ). These findings suggest that pretreatment with CQ at clinically relevant concentrations can downregulate OATP1B1-mediated transport in OATP1B1-overexpressing cell lines and accumulation of pitavastatin in human SCH. Pitavastatin is a substrate of multiple OATP transporters, including OATP1B1, 1B3, and 2B1. 60, 66 Currently, there is no known specific probe substrate or inhibitor of OATP1B1 available. This is a technical challenge to specifically study the transport function of endogenous OATP1B1 in primary human hepatocytes. Therefore, from our current study, we cannot draw a conclusion regarding whether transport function of endogenous OATP1B1 is downregulated by CQ in human SCH. The current study does not exclude the possibility that CQ may affect transport activity of other transporters in human SCH. Decreased pitavastatin accumulation in human SCH following CQ pretreatment (10 μM, 5 h) may represent a net effect of CQ on hepatic transport of pitavastatin. Further studies are warranted to determine whether other OATP transporters, including the closely related family member OATP1B3, can also be regulated by CQ.
The inhibitory effects of CQ toward OATP1B1 transport activity at clinically relevant concentrations led to our hypothesis that concurrent use of CQ and statins may have a higher myopathy risk than statins alone in patients. Pharmacoepidemiologic studies using data from the FAERS was utilized to test our hypothesis. Since CQ is a substrate and inhibitor of multiple CYP enzymes, 67, 68 to minimize potential CYP450 mediated DDIs, we selected three statins, pitavastatin, rosuvastatin, and pravastatin, which are minimally metabolized through CYP450 enzymes, 34, 35, 69 in our pharmacoepidemiologic studies. Increased systemic exposure of these statins has been reported in subjects bearing the V174A polymorphism of OATP1B1 (reviewed by Niemi 32 ). Our data indicated that CQ plus these three statins is associated with increased risk of myopathy compared to these statins alone (Table 3 ). This result is consistent with the in vitro inhibitory effects of CQ toward OATP1B1-mediated transport and pitavastatin accumulation in human SCH following pretreatment at clinically relevant concentrations. Taken together, combination of our data from in vitro and pharmacoepidemiologic studies supports that potential OATP-mediated DDIs caused by CQ are likely.
A higher myopathy risk in women than men was observed in both the statins alone group and the CQ plus statins group (Table 3 ). The relative risk of myopathy (CQ plus statins vs statins alone) reaches a statistically significant level only in women, but not in men (Table  3) . These findings are consistent with what we have observed in the medical record database 76 and reports from others 61, 77 that females have higher risk for myopathy than males. Smaller vascular volumes and reduced muscle mass in females, which may result in greater tissue drug exposure per statin dose, are possible reasons of higher myopathy risk in women. 61 Higher systemic exposure of statins in women was observed for pitavastatin, 78 while there is no gender difference in systemic exposure of pravastatin. 79 For rosuvastatin, one study reported higher AUC and C max in women than in men, 80 while no gender difference was observed for rosuvastatin pharmacokinetics in another study. 81 The gender difference in pharmacokinetics of CQ and the effects of CQ on pharmacokinetics of statins have not been reported. A clinical DDI study determining the effects of CQ on systemic exposure of statins in women and men may help to elucidate the potential mechanism underlying the higher myopathy risk in patients in whom CQ and statins are administered concurrently compared with statins alone.
Recently, the effects of pretreatment on OATP1B1-mediated transport were reported for several OATP1B1 inhibitors. Pretreatment with cyclosporine, 70 saquinavir, ritonavir, 71 simeprevir, asunaprevir, or daclatasvir 72 significantly decreases OATP1B1-mediated transport. Pretreatment with cyclosporine decreased the apparent IC 50 values toward OATP1B1 inhibition. 31, 73 In current studies, without CQ pre-incubation, CQ at concentrations 5-100 μM did not affect [ 3 H]E 2 17G accumulation (1 μM, 2 min) in HEK293-OATP1B1 cells ( Figure 4D ). This result is consistent with a recent report that 10 μM CQ did not affect OATP1B1-mediated estrone-3-sulfate transport. 15 However, when [ 3 H]E 2 17G accumulation was determined in the presence of CQ following CQ preincubation, CQ, an apparent non-inhibitor of OATP1B1 determined without pre-incubation ( Figure 4D ), significantly decreased OATP1B1-mediated transport ( Figure 4E ). The current study reports a novel inhibitory effect of lysosomotropic drug CQ toward OATP1B1-mediated transport, where an apparent noninhibitor CQ "gained" its inhibitory effect toward OATP1B1 after pre-incubation. In clinical conditions, a perpetrator drug may be administered prior to the victim drug. A perpetrator drug and a victim drug may coexist in the body for a period of time that is longer than the in vitro incubation time used to determine the perpetrator/substrate interaction (a few minutes in many cases). Our results together with others 31, 73, 74 highlight the importance of introducing a pre-incubation step when assessing the OATP1B1-mediated DDI potential of an investigational drug in vitro. The current approach of using the OATP1B1 inhibition tree and R-value to assess OATPmediated DDIs in vitro assumes competitive transporter inhibition by investigational drugs. 75 Our data support that mechanism(s) other than competitive inhibition of OATP1B1 transport activity may also be important in causing OATP1B1-mediated DDIs.
The finding that CQ pretreatment increased total OATP1B1 protein levels, but decreased OATP1B1 transport activity, may seem paradoxical at first. However, transporter function is not always correlated with the total protein levels of the transporters. For example, following PKC activation, the total protein levels of OATP1B3, 41 OATP1A2, 82 and OAT1 and OAT4 83, 84 were not affected while their transport function was significantly decreased. CQ pretreatment decreased V max without affecting the K m values of OATP1B1-mediated [ 3 H]E 2 17G transport (Figure 8) . A similar trend of decreased V max and unaffected K m was reported for OATP1A2 82 and OAT1,3 and 4, 83-85 dopamine transporter, 86 and sodiumglucose transporter (SGLT1) 87 upon PKC activation. In these previous studies, the decreased V max of substrate transport was associated with decreased surface levels for OATP1A2, 82 OAT1, 3 and 4, 83-85 increased phosphorylation for dopamine transporter, 86 or decreased turnover rate but unaltered surface levels for SGLT1. 87 CQ has been reported to affect cell surface levels of several plasma membrane proteins such as the tumor necrosis factor receptor (TNF-R), 88 the α-macroglobulin-protease (αM-P) surface receptors, 89 and BMPR-II. 62 Short-term treatment with monensin and bafilomycin A1, which have lysosome inhibition activity, also resulted in significantly decreased OATP1B1-mediated transport ( Figure 5 ). In addition to inhibiting lysosomal activity, CQ, monensin, and bafilomycin A1 have other effects such as affecting trafficking of the membrane protein. 90 The exact mechanism(s) through which CQ, monensin, and bafilomycin A1 downregulate transport function of OATP1B1 remain unknown and warrant further investigation.
In conclusion, the present studies report novel findings that CQ inhibits lysosome degradation of OATP1B1 protein; pre-incubation with CQ downregulates OATP1B1-mediated transport in stable cell lines, and decreases pitavastatin uptake in human SCH. Our in vitro data in combination with pharmacoepidemiologic studies support that CQ has potential to cause OATP-mediated DDIs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Effects of CQ on total protein levels of OATP1B1 and Na,K-ATPase in HEK293-OATP1B1 cells and on OATP1B1 total protein levels in human SCH. HEK293-OATP1B1 cells were seeded in 24-well plates at 1.1 × 10 5 cells/well, and were cultured for 48 h prior to treatment. Human SCH were cultured as described in the Experimental Section. WCL was prepared by directly lysing the cells in the culture plate without trypsinization. Representative immunoblot images of OATP1B1 (A) and Na,K-ATPase (B) in WCL of HEK293-OATP1B1 pretreated with CQ (25 or 100 μM) or CTL for indicated times are
shown. GAPDH were used as the loading control for A and B. OATP1B1 and Na,K-ATPase protein levels determined by densitometry were normalized to levels of GAPDH. Fold changes of total protein levels of OATP1B1 in A and Na,K-ATPase in B (CQ vs CTL) are expressed as mean ± SD (n = 4 for both A and B). Colocalization of FLAG-OATP1B1 and LAMP-2 in HEK293-FLAG-OATP1B1 cells.
Coimmunofluorescence staining of FLAG-OATP1B1 (red) and LAMP-2 (green) was performed in HEK293-FLAG-OATP1B1 cells treated with vehicle CTL or 25 μM CQ for 2 and 5 h as described in the Experimental Section. White arrow heads indicate the accumulation of FLAG-OATP1B1 inside the LAMP-2-positive vacuoles. Nuclei were counterstained with DAPI (blue). Images were taken using Olympus FV1000 confocal microscope. Representative images from the same experiments are shown (3 and 2 separate experiments for 2 h and 5 h treatment, respectively). 
